Verheul Henk M W, Pinedo Herbert M
Dept of Internal Medicine, University Medical Center, Utrecht, The Netherlands.
Expert Opin Emerg Drugs. 2005 May;10(2):403-12. doi: 10.1517/14728214.10.2.403.
Treatment with antiangiogenic agents as standard anticancer therapy with or without classical chemotherapy is rapidly approaching. The clinical efficacy of bevacizumab in colorectal cancer in combination with chemotherapy caused a revival of the antiangiogenic strategy. By combining this agent with a tyrosine kinase receptor epidermal growth factor receptor blocker (erlotinib), remarkable responses were seen in renal cell cancer. It has been thought that blocking these biological pathways would cause no drug-related toxicity, but a whole new pattern of relatively mild side effects compared with classical chemotherapy, including skin rash, fatigue and hypertension, has been observed. In combination with chemotherapy, other serious side effects, such as bleeding and thrombosis, also occur. Here, the preclinical and clinical data of antiangiogenic agents in clinical trials at this moment are summarised.
将抗血管生成药物作为标准抗癌疗法，无论是否联合传统化疗，这种治疗方式正在迅速成为现实。贝伐单抗联合化疗在结直肠癌治疗中的临床疗效使得抗血管生成策略得以复兴。将该药物与酪氨酸激酶受体表皮生长因子受体阻滞剂（厄洛替尼）联合使用时，在肾细胞癌中观察到了显著疗效。过去认为阻断这些生物学途径不会产生与药物相关的毒性，但现已观察到与传统化疗相比，出现了一种全新的相对轻微的副作用模式，包括皮疹、疲劳和高血压。联合化疗时，还会出现其他严重副作用，如出血和血栓形成。在此，总结了目前抗血管生成药物在临床试验中的临床前和临床数据。
